Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis

Inclusion Criteria: * 18 years old and older * Relapsing remitting (RR) secondary progressive (SP) or primary progressive multiple sclerosis according to McDonald 2005 (Polman) MS diagnostic criteria. * Affected of fatigue for more than 3 months with global score on Modified Fatigue Impact Scale (MFIS)\>45. * Indication of treatment of fatigue to the appreciation of the neurologist. * Expanded Disability Status Scale (EDSS) not exceeding 6.0. * Information and comprehensive agreement signed by patient and the investigator. * Subject affiliated to health insurance coverage. Exclusion Criteria: * Patients with serious unstable disease : * recurrent or serious relapses * rapidly ongoing disability impairment in the preceding 6 months * serious or non stabilized depression * Patients starting a new disease modifying therapy, immunosuppression or antidepressant therapy less than 3 months ago or not stabilized. * Patients with a treatment of fatigue or of other condition that may interfere with fatigue evaluation to the appreciation of the neurologist. * Energy drinks consumption or toxicomania. * All other reasons to the opinion of the neurologist that may impair study management, especially patient compliance, neuro-psychological disorders that may input questionnaires filling. * Person under protection of the law. * Participation in other clinical trials (allowing for exceptions, after recommendation from the scientific council).